You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
N/A
SBC: EDAPTIVE COMPUTING INC Topic: N/AN/A
STTR Phase II 1999 Department of DefenseDefense Advanced Research Projects Agency -
N/A
SBC: Receptorpro, Inc. Topic: N/AN/A
STTR Phase II 2000 Department of Health and Human ServicesNational Institutes of Health -
A Novel Apoptosis Assay with Antibodies to ssDNA
SBC: APOSTAIN, INC. Topic: N/ADESCRIPTION (Provided by Applicant): Work performed during the Phase I of this project has demonstrated that formamide induces selective denaturation of DNA in apoptotic cells. This novel effect of formamide on the stability of apoptotic DNA combined with the detection of denatured DNA with monoclonal antibody (MAb)against single-stranded DNA, has made it possi ...
STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health -
Audio-Vestibular Testing for Bedside/Other Applications
SBC: INTELLIGENT HEARING SYSTEMS CORP Topic: N/ADESCRIPTION: (Adapted from applicant's abstract): A potentially effective way of limiting or preventing drug-induced cochleo- and vestibulo-ototoxicity is monitoring during treatment. However, practical, cost-effective, monitoring programs are difficult to establish due to impractical instrumentation. Current practices also tend to neglect the balance system. Research ...
STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health -
Enteric Elimination and Degradation of Oxalic Acid
SBC: IXION BIOTECHNOLOGY, INC. Topic: N/AApproximately one million cases of stone disease are diagnosed in the United States every year and hyperoxaluria is considered to be a major risk factor. Our goal is to reduce the burden of oxalate excretion by the kidneys before the onset of renal failure caused by the oxalate-induced insults of hyperoxaluria, oxalate crystal deposition in tissue, and the formation of calcium oxalate stones. The ...
STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health -
GLYCOSAMINOGLYCANS: TREATMENT FOR ALZHEIMER'S DISEASE
SBC: NEUROSTRUCTURAL ANALYSIS, LTD Topic: N/ADESCRIPTION (adapted from applicant's abstract): The long-term objective of this proposal is to find novel treatment strategies in Alzheimer's disease. Phase I of this Small Business Technology Transfer application focused on C3, an ultra low molecular weight product of fractionated heparin. C3, a glycosaminoglycan (GAG), is composed mainly of 4-10 oligosac ...
STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health -
M3 RECEPTOR--DIAGNOSTIC MARKER FOR SJOGREN'S SYNDROME
SBC: IXION BIOTECHNOLOGY, INC. Topic: N/ADESCRIPTION (provided by applicant): Sjogren's syndrome is a human autoimmune disease of the salivary and lacrimal glands that results in a debilitating xerostomia (dry mouth) and xerophthalmia (dry eyes). This syndrome may present as either a primary autoimmune disease or as a secondary autoimmune disease most often concomitant with other connective tissue diseases or diabetes. Although classi ...
STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health -
Cytochlor/cytofluor: New Tumor Targeted Radiosensitizer
SBC: HALOGENETICS Topic: N/ADESCRIPTION (provided by applicant): Cytochlor Technology is about to enter a Phase I trial as a radiosensitizer of tumors of the oral cavity and oropharynx with NCI supervision. Our objective is to demonstrate Cytochlor's safety, selectivity and possible efficacy (although efficacy is not the goal of a Phase I trial). Our goal is to move Cytochlor Technology to a mutliinstitutional Phase II clini ...
STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health -
Evolutionary Analysis of Protein using HyperChem
SBC: HYPERCUBE Topic: N/ADESCRIPTION (provided by applicant): At the end of Phase II, we will launch a new commercial product: HYPERPROTEIN. HYPERPROTEIN will be built on an existing software platform, HYPERCHEM, now in its commercial Version 7.5. HYPERCHEM is used in both education and industry to apply molecular modeling and computational chemistry to molecules. The feasibility of placing the HYPERPROTEIN product on th ...
STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health -
New Broad Band Rare-Earth-Doped Glasses For Optical Fiber Communications
SBC: KIGRE, INC. Topic: BMDO01T001Kigre is developing new scalable high gain broad band rare earth doped laser oscillator/amplifier glass materials & diode pump architectures in support of high energy and high power laser applications. What's new, exciting and different about Kigre's laser glass materials and constructs is the ability to efficiently store and extract 1000-10,000x more laser power from ultra-short gain lengths and ...
STTR Phase II 2004 Department of DefenseDefense Advanced Research Projects Agency